SK Biopharmaceuticals Receives AAA Rating in MSCI ESG Assessment for Second Consecutive Year

Achieved Global Top 4
Ranking Up Three Spots from Last Year

On September 10, SK Biopharmaceuticals announced that it has received the highest AAA rating in this year's ESG (Environmental, Social, and Governance) assessment by Morgan Stanley Capital International (MSCI), a global ESG rating agency. SK Biopharmaceuticals has maintained the AAA rating for two consecutive years, making it the only domestic pharmaceutical and biotechnology company included in the global AAA group.

This year's ESG assessment was conducted under even stricter standards and intense competition. MSCI evaluates approximately 8,500 listed companies worldwide each year across environment, social, and governance categories. Among 203 pharmaceutical companies assessed this year, only six companies (3%) received the AAA rating, with SK Biopharmaceuticals ranking fourth among global pharmaceutical companies. Notably, SK Biopharmaceuticals' achievement stands out even more as some major pharmaceutical companies saw their ratings downgraded, causing leading global firms to falter.

SK Biopharmaceuticals has demonstrated outstanding competitiveness in key areas such as human capital management, ethical management, and quality and safety control. By operating a systematic talent pipeline strategy and a company-wide performance evaluation system, the company has strengthened its human capital capabilities. Under board supervision, it has established a whistleblower protection system and regular ethical audit framework, thereby reinforcing a foundation of trust. Additionally, through quality training, rigorous testing management, and responsible marketing policies, the company has proven that a corporate culture prioritizing patient safety is firmly in place.

The AAA rating demonstrates that SK Biopharmaceuticals has met the highest standards in each category amid fierce global ESG competition. Having proven its competitiveness in core ESG areas through continuous change and development, SK Biopharmaceuticals plans to continue sustainable growth and create social value by making ESG a core management strategy moving forward.

Lee Donghun, CEO of SK Biopharmaceuticals, stated, "Being the only domestic company to maintain the AAA rating for two consecutive years in the face of strengthened global ESG evaluation standards is proof that SK Biopharmaceuticals' sustainable management system is recognized as top-tier globally. Going forward, as a global new drug development company, we will continue to fulfill our social responsibilities and provide sustainable value to patients and society."

This content was produced with the assistance of AI translation services.